您搜索了: directed (罗马尼亚语 - 英语)

khers (ursul), directed by khosro masumi
khers (the bear), directed by khosro masumi

sad sal beh een salha (a hundred years like this), directed by saman moghadam
sad sal beh een salha (a hundred years like this), directed by saman moghadam

directed by oliver stone", the american historical review 110:2, 553 (2005).
directed by oliver stone", the american historical review 110:2, 553 (2005).

având ca directed pe umanosuke iida, seria a fost bazată pe manga, dar a folosit un scenariu de chiaki konaka și este diferită de manga în ceea ce privește intriga, deși folosește aceleași personaje și un desing al acestora asemănător cu manga.
directed by umanosuke iida, the series was based on the manga, but used a screenplay by chiaki konaka and is significantly different from the manga in terms of plot, though it uses some of the same characters and similar character designs.

pauluhn j. and thiel a. (2007), a simple approach to validation of directed-flow nose-only inhalation, chambers.
pauluhn j and thiel a (2007). a simple approach to validation of directed-flow nose-only inhalation chambers.

abstract intravenous thrombolysis with recombinant tissue plasminogen activator (rt-pa) is the established treatment for acute ischemic stroke patients presenting within 4.5 h of stroke onset based on the results of the national institute of neurological disorders and stroke study group trial and european cooperative acute stroke study iii. in a significant number of patients, however, intravenous thrombolysis with rt-pa remains ineffective, with lower rates of recanalization, especially for proximal occlusions and a large thrombus burden. newer thrombolytic agents, such as reteplase, tenecteplase or desmoteplase, offer pharmacokinetic and hemodynamic advantages over rt-pa and have been, or are currently being, tested for safety and efficacy in clinical trials. agents such as direct fibrinolytics that do not depend on the availability of plasminogen are also being studied in ongoing trials. endovascular revascularization is an evolving treatment option enabling mechanical clot disruption or extraction in combination with local directed pharmacological thrombolysis. several new endovascular devices have been successfully tested for safety in acute ischemic stroke patients and are now being tested for efficacy in larger clinical trials. continued innovation and refinement of endovascular technology and techniques, including combination therapy such as bridging therapy and the use of stent-like devices, is expected to increase technical success and improve overall efficacy and
abstract intravenous thrombolysis with recombinant tissue plasminogen activator (rt-pa) is the established treatment for acute ischemic stroke patients presenting within 4.5 h of stroke onset based on the results of the national institute of neurological disorders and stroke study group trial and european cooperative acute stroke study iii. in a significant number of patients, however, intravenous thrombolysis with rt-pa remains ineffective, with lower rates of recanalization, especially for proximal occlusions and a large thrombus burden. newer thrombolytic agents, such as reteplase, tenecteplase or desmoteplase, offer pharmacokinetic and hemodynamic advantages over rt-pa and have been, or are currently being, tested for safety and efficacy in clinical trials. agents such as direct fibrinolytics that do not depend on the availability of plasminogen are also being studied in ongoing trials. endovascular revascularization is an evolving treatment option enabling mechanical clot disruption or extraction in combination with local directed pharmacological thrombolysis. several new endovascular devices have been successfully tested for safety in acute ischemic stroke patients and are now being tested for efficacy in larger clinical trials. continued innovation and refinement of endovascular technology and techniques, including combination therapy such as bridging therapy and the use of stent-like devices, is expected to increase technical success and improve overall efficacy and time to recanalization with minimal procedure-related morbidity in the treatment of acute ischemic stroke. introduction stroke is the third leading cause of death and a leading cause of disability in most western countries. in the usa, approximately 780,000 individuals suffer a stroke annually, up to half of which are ischemic strokes caused by occlusion of the cerebral arteries. there has been a paradigm shift in acute ischemic stroke care since the approval of intravenous tissue plasminogen activator (tpa) based on the results of the national institute of neurological disorders and stroke (ninds) trial. with the advent of newer devices, endovascular treatment for acute ischemic stroke is being increasingly employed, especially for patients outside the traditional time window for treatment and those ineligible for pharmacological thrombolysis. section 1 of 22